文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

低剂量率近距离放疗等待时间过长增加中危前列腺癌复发与转移风险

Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-07-01

该研究回顾性分析了2003至2016年间单中心接受低剂量率近距离放疗的466例中危前列腺癌患者,中位等待时间5.1个月、中位随访8.1年。结果显示在NCCN不良中危亚组中,等待时间每增加1个月,复发累积发生率显著增加(MHR=1.01/月,95%CI 1.00-1.03,P=0.044),转移风险显著增加(MHR=1.04/月,95%CI 1.02-1.06,P<0.001);在有利中危亚组中无显著关联。

要点

  • NCCN不良中危前列腺癌患者LDR-BT等待时间每增1个月,复发风险增1%、转移风险增4%。
  • NCCN有利中危患者中等待时间与复发或转移风险无显著关联。
  • 全部中危患者中等待时间与转移发生率增加相关,但与总生存无关联。

核心结论

  • 在NCCN不良中危前列腺癌患者中,LDR-BT等待时间延长可预测复发累积发生率和转移风险增加。
  • 在NCCN有利中危患者中,等待时间与复发或转移风险无显著关联。
  • 全部中危患者中,等待时间与转移发生率增加相关,但与总生存无关联。

研究设计与样本

  • 单中心回顾性研究,纳入2003至2016年间接受LDR-BT的466例中危前列腺癌患者。
  • 等待时间定义为从活检至LDR-BT的时间。
  • 采用Cox和Fine-Gray回归进行单变量和多变量模型分析。

主要发现

  • 全部患者中位随访8.1年(四分位距6.3-10.4年),中位等待时间5.1个月(四分位距3.9-6.9个月)。
  • NCCN不良中危患者170例(36%),多变量模型中等待时间每增1个月复发风险MHR=1.01(95%CI 1.00-1.03,P=0.044),转移风险MHR=1.04(95%CI 1.02-1.06,P<0.001)。
  • NCCN有利中危患者中等待时间与复发或转移风险无显著关联。
  • 全部中危患者中,多变量模型显示等待时间与转移发生率增加相关(MHR=1.03/月,95%CI 1.02-1.05,P<0.001),但与复发无显著关联。
  • UIR、FIR及全部中危队列中等待时间与总生存均无关联。

关键数值与推荐

  • NCCN不良中危患者等待时间每增加1个月,复发风险增加1%(MHR=1.01,95%CI 1.00-1.03,P=0.044)。
  • NCCN不良中危患者等待时间每增加1个月,转移风险增加4%(MHR=1.04,95%CI 1.02-1.06,P<0.001)。
  • 全部中危患者等待时间每增加1个月,转移风险MHR=1.03(95%CI 1.02-1.05,P<0.001)。

临床怎么用

  • 对NCCN不良中危前列腺癌患者应尽量减少LDR-BT的等待时间,以降低复发和转移风险。
  • 该中心公共医疗系统资源限制导致等待名单超过5个月,提示需关注等待时间对预后的影响。

局限性

  • 单中心回顾性研究,结果可能受该中心公共医疗系统资源限制等混杂因素影响。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: It has previously been shown that increased wait times for prostatectomy are associated with poorer outcomes in intermediate-risk prostatic carcinoma (PCa). However, the impact of wait times on PCa outcomes following low-dose-rate brachytherapy (LDR-BT) are unknown. METHODS AND MATERIALS: We retrospectively reviewed 466 intermediate-risk PCa patients that underwent LDR-BT at a single comprehensive cancer center between 2003 and 2016. Wait times were defined as the time from biopsy to LDR-BT. The association of wait times with outcomes was evaluated using Cox and Fine-Gray regression in both univariate and multivariate models. RESULTS: Median (interquartile range) follow-up and wait time for all patients were 8.1 (6.3-10.4) years and 5.1 (3.9-6.9) months, respectively. Among NCCN unfavourable intermediate-risk (UIR) patients (n = 170; 36%), increased wait times predicted both a greater cumulative incidence of recurrence [MHR = 1.01/month of wait time (95% CI: 1.00-1.03); P = 0.044] and metastases [MHR = 1.04/month of wait time (95% CI: 1.02-1.06); P < 0.001] in multivariate modeling. In NCCN favourable intermediate-risk (FIR) patients, there was no significant association between wait time and recurrence or metastases risk. Among all intermediate-risk patients, wait time was associated with an increase in the incidence of metastases [MHR = 1.03/month of wait time (95% CI: 1.02-1.05); P < 0.001], but not recurrence in multivariate models. There was no association between wait time and overall survival in the UIR, FIR, or all intermediate-risk cohorts. CONCLUSIONS: Resource constraints within this center's public healthcare system have contributed to waitlists exceeding 5-months in length. This study finds that patients with UIR PCa experience a 1% increase in the risk of recurrence and 4% increase in the risk of metastases with each additional month of delay in definitive disease management. Preventing such extended management delays in LDR-BT may improve disease-related outcomes in patients with PCa.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Khanolkar RA, Quon H, Thind K, et al. Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma. Clin Transl Radiat Oncol. 2021. PMID: 34307912. doi:10.1016/j.ctro.2021.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。